Next Article in Journal / Special Issue
Dual Targeting of Tumor Cells with Bispecific Single-Chain Fv-Immunoliposomes
Previous Article in Journal
Current and Potential Uses of Immunocytokines as Cancer Immunotherapy
Previous Article in Special Issue
A Cassette Vector System for the Rapid Cloning and Production of Bispecific Tetravalent Antibodies
Article Versions
Related Info
More by Authors
Share This Article
  •  Twitter
  •  Facebook
  •  Mendeley
  •  CiteULike
  • More services
Antibodies 2012, 1(2), 172-198; doi:10.3390/antib1020172
Review

Cancer Immunotherapy by Retargeting of Immune Effector Cells via Recombinant Bispecific Antibody Constructs

1,†
, 1
, 1
, 1
, 1
, 1
, 1
, 1
, 1
, 1
 and 1,2,*
Received: 24 May 2012 / Revised: 27 June 2012 / Accepted: 10 July 2012 / Published: 18 July 2012
(This article belongs to the Special Issue Bispecific Antibodies for Dual Targeting Strategies)
View Full-Text   |   Download PDF [623 KB, uploaded 18 July 2012]   |   Browse Figures
Abstract: Immunotherapy has emerged as an alternative strategy to treat malignancies in addition to conventional radio- and chemotherapy. There has been a plethora of evidence that the immune system is able to control tumor outgrowth and a number of strategies have been put forward to utilize this ability for immunotherapy. However, some of these strategies have not been very efficient and their success has been limited by tumor evasion mechanisms. A promising approach to engage effector cells of the immune system overcoming some of the escape mechanisms has been introduced more than two decades ago. This approach is based on bispecific antibodies. Here we summarize the evolution of bispecific antibodies, their improvement, remaining obstacles and some controversial reports.
Keywords: cancer immunotherapy; monoclonal antibodies; antibody engineering; bispecific antibodies cancer immunotherapy; monoclonal antibodies; antibody engineering; bispecific antibodies
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Stamova, S.; Koristka, S.; Keil, J.; Arndt, C.; Feldmann, A.; Michalk, I.; Bartsch, H.; Bippes, C.C.; Schmitz, M.; Cartellieri, M.; Bachmann, M. Cancer Immunotherapy by Retargeting of Immune Effector Cells via Recombinant Bispecific Antibody Constructs. Antibodies 2012, 1, 172-198.

AMA Style

Stamova S, Koristka S, Keil J, Arndt C, Feldmann A, Michalk I, Bartsch H, Bippes CC, Schmitz M, Cartellieri M, Bachmann M. Cancer Immunotherapy by Retargeting of Immune Effector Cells via Recombinant Bispecific Antibody Constructs. Antibodies. 2012; 1(2):172-198.

Chicago/Turabian Style

Stamova, Slava; Koristka, Stefanie; Keil, Juliane; Arndt, Claudia; Feldmann, Anja; Michalk, Irene; Bartsch, Holger; Bippes, Claudia C.; Schmitz, Marc; Cartellieri, Marc; Bachmann, Michael. 2012. "Cancer Immunotherapy by Retargeting of Immune Effector Cells via Recombinant Bispecific Antibody Constructs." Antibodies 1, no. 2: 172-198.


Antibodies EISSN 2073-4468 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert